EMA/149012/2022

European Medicines Agency decision

P/0142/2022

of 13 April 2022

on the acceptance of a modification of an agreed paediatric investigation plan for galcanezumab (Emgality), (EMEA-001860-PIP03-16-M07) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0142/2022

of 13 April 2022

on the acceptance of a modification of an agreed paediatric investigation plan for galcanezumab (Emgality), (EMEA-001860-PIP03-16-M07) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0341/2016 issued on 5 December 2016, the decision P/0137/2018 issued on 7 May 2018, the decision P/0111/2019 issued on 22 March 2019, the decision P/0248/2019 issued on 16 July 2019, the decision P/0136/2020 issued on 15 April 2020 and the decision P/0449/2021 issued on 29 October 2021,

Having regard to the application submitted by Eli Lilly and Company Limited on 18 November 2021 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 25 February 2022, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for galcanezumab (Emgality), solution for injection, subcutaneous use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Eli Lilly and Company Limited, 8 Arlington Square West, Downshire Way, RG12 1PU – Bracknell, United Kingdom.

EMA/PDCO/709738/2021
Amsterdam, 25 February 2022

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-001860-PIP03-16-M07

Scope of the application

Active substance(s):

Galcanezumab

Invented name:

Emgality

Condition(s):

Prevention of migraine headaches

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Subcutaneous use

Name/corporate name of the PIP applicant:

Eli Lilly and Company Limited

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Eli Lilly and Company Limited submitted to the European Medicines Agency on 18 November 2021 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0341/2016 issued on 5 December 2016, the decision P/0137/2018 issued on 7 May 2018, the decision P/0111/2019 issued on 22 March 2019, the decision P/0248/2019 issued on 16 July 2019, the decision P/0136/2020 issued on 15 April 2020 and the decision P/0449/2021 issued on 29 October 2021.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 4 January 2022.

Scope of the modification

Some measures of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition

Prevention of migraine headaches

The waiver applies to:

- the paediatric population from birth to less than 6 years of age;
- solution for injection, subcutaneous use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric investigation plan

2.1. Condition

Prevention of migraine headaches

2.1.1. Indication(s) targeted by the PIP

Prophylactic treatment of migraine headache

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 years to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Solution for injection

2.1.4. Measures

Area	Description
Quality-related studies	Not applicable
Non-clinical studies	**Study 1** Enhanced pre- and postnatal development reproductive toxicity study in rats **Study 2** Definitive juvenile toxicity study in rats **Study 3** Fertility and early embryonic development reproductive toxicity study

Clinical studies	**Study 4** Randomised double-blind placebo-controlled study trial to evaluate pharmacokinetics, safety, efficacy, of galcanezumab in children from 6 to less than 18 years of age with episodic migraine (I5Q-MC-CGAS) **Study 5** Randomised double-blind placebo-controlled study trial to evaluate, safety, efficacy, of galcanezumab in paediatric patients from 12 to less than 18 years of age with chronic migraine (I5Q-MC-CGAT).
Extrapolation, modelling and simulation studies	**Study 6** Modelling and simulation study, to support initial dose determination of galcanezumab in children from 6 to less than 18 years of age with migraine and further paediatric development
Other studies	Not applicable
Other measures	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By February 2024
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Prevention of migraine

Authorised indication(s):

- Emgality is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.

Authorised pharmaceutical form(s):

Solution for injection

Authorised route(s) of administration:

Subcutaneous use